Chemours Co
Close on Oct 19, 2026
- Market cap
- $1.91B
- P/E (TTM)
- –
- Dividend yield
- 4.06%
Earnings
Next report expected Nov 5, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 4, 2026 | After market close | $1.59B | $-1.81 | $0.42 |
| Q1 FY2026 Ended Mar 31, 2026 | May 5, 2026 | After market close | $1.38B | $-0.19 | $0.05 |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 19, 2026 | After market close | $1.33B | $-0.31 | $0.05 |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | After market close | – | $0.40 | $0.20 |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 5, 2025 | After market close | – | $-2.54 | $0.58 |
| Q1 FY2025 Ended Mar 31, 2025 | May 6, 2025 | After market close | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 18, 2025 | Before market open | – | $-0.05 | $0.11 |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 4, 2024 | Before market open | – | $-0.18 | $0.40 |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 1, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | Apr 30, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 28, 2024 | After market close | – | – | – |
Company guidance
Outlook given with results on Aug 4, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Capital expenditures | Full Year 2026 | $250.00M to $280.00M | Lowered |
| capital expenditures | third quarter | $65.00M | New |
| Adjusted EBITDAnon-GAAP | third quarter | $20.00M to $30.00M | Lowered |
| Adjusted EBITDAnon-GAAP | Full Year 2026 | $775.00M to $825.00M | Lowered |
| Free Cash Flowsnon-GAAP | third quarter | $50.00M | New |
| Free Cash Flowsnon-GAAP | Year Ended December 31, 2026 | $195.00M to $245.00M | Raised |
| Free Cash Flow Conversionnon-GAAP | Full Year 2026 | $25.00M | Lowered |
| Adjusted Net Incomenon-GAAP | Year Ending December 31, 2026 | $120.00M to $145.00M | Raised |
| Corporate Expenses | third quarter | $40.00M to $45.00M | New |
| Net loss attributable to ChemoursGAAP | Year Ending December 31, 2026 | -$255.00M to -$230.00M | Lowered |
| net leverage rationon-GAAP | end of 2026 | 3.8 | Maintained |
| Net Sales | Full Year 2026 | 1% to 5% growth | Lowered |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Chemours filed with the SEC
Chemours, DuPont and Corteva Reach Agreement to Resolve PFAS-Related Claims in North Carolina
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
THE CHEMOURS COMPANY Investor Presentation September 2026
Regulation FD disclosure · EX-99.1 to Form 8-K
The Chemours Company Reports Second Quarter Results
Results of operations · EX-99.1 to Form 8-K
Chemours Reaches Agreement with U.S. EPA to Resolve Claims Relating to PFAS
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
The Chemours Company Reports First Quarter Results
Results of operations · EX-99.1 to Form 8-K
The Chemours Company Announces Completion of Private Offering of $700,000,000 Aggregate Principal Amount of 7.875% Senior Unsecured Notes Due 2034
Material agreement · New financial obligation · Other events · EX-99.1 to Form 8-K
The Chemours Company Announces Private Offering of $600,000,000 of Senior Notes Due 2034
Other events · EX-99.1 to Form 8-K
The Chemours Company Announces Upsizing and Pricing of Private Offering of $700,000,000 of 7.875% Senior Notes Due 2034
Other events · EX-99.2 to Form 8-K
The Chemours Company Reports Fourth Quarter and Full Year 2025 Results
Results of operations · EX-99.1 to Form 8-K
The Chemours Company Agrees to Sell Former Titanium Dioxide Site in Taiwan
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
The Chemours Company Reports Third Quarter 2025 Results
Results of operations · EX-99.1 to Form 8-K
Q3 2025 Financial Prepared Remarks
Results of operations · EX-99.2 to Form 8-K
Dordrecht, NL trade register no. 54013445
Material agreement · New financial obligation · Other events · EX-99.1 to Form 8-K
The Chemours Company Reports Second Quarter 2025 Results
Results of operations · EX-99.1 to Form 8-K
Q2 2025 Financial Prepared Remarks
Results of operations · EX-99.2 to Form 8-K
Chemours, DuPont and Corteva Reach Agreement with the State of
Material agreement · Other events · EX-99.1 to Form 8-K
The Chemours Company Reports First Quarter 2025 Results
Results of operations · EX-99.1 to Form 8-K
FOURTH AMENDMENT TO AMENDED AND RESTATED RECEIVABLES PURCHASE AGREEMENT
Other events · EX-99.1 to Form 8-K
EXHIBIT A TO THE THIRD FOURTH AMENDMENT, DATED AS OF
Other events · EX-99.2 to Form 8-K
The Chemours Company Reports Fourth Quarter and Full Year 2024 Results
Results of operations · EX-99.1 to Form 8-K
Chemours Appoints Leslie M. Turner to its Board of Directors
Executive or director change · Other events · EX-99.1 to Form 8-K
The Chemours Company Announces Completion of Euro denominated Term Loan Repricing
Material agreement · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K
The Chemours Company Announces Completion of U.S. Dollar-denominated Term Loan Repricing
Material agreement · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K
The Chemours Company Announces Completion of Private Offering of $600,000,000 Aggregate Principal Amount of 8.000% Senior Unsecured Notes Due 2033
Material agreement · New financial obligation · Other events · EX-99.1 to Form 8-K
The Chemours Company Announces Private Offering of $600,000,000 of Senior Notes Due 2033
Other events · EX-99.1 to Form 8-K
The Chemours Company Announces Pricing of Private Offering of $600,000,000 of 8.000% Senior Notes Due 2033
Other events · EX-99.2 to Form 8-K
The Chemours Company Reports Third Quarter 2024 Results and
Results of operations · EX-99.1 to Form 8-K
Third Quarter 2024 Earnings Presentation November 4, 2024 Exhibit 99.2
Results of operations · EX-99.2 to Form 8-K
The Chemours Company Investor Presentation August 2024
Regulation FD disclosure · EX-99.1 to Form 8-K
The Chemours Company Reports Second Quarter 2024 Results
Results of operations · EX-99.1 to Form 8-K
The Chemours Company Temporarily Pauses Titanium Dioxide Production at Altamira, Mexico Site Amid Severe Regional Drought
Other events · EX-99.1 to Form 8-K
The Chemours Company Reports First Quarter 2024 Results
Results of operations · EX-99.1 to Form 8-K
Transcript The Chemours Company, Q4 2023 Earnings Call, Mar 28, 2024
Regulation FD disclosure · EX-99.1 to Form 8-K
Chemours Announces Completion of Planned Procedures by the Audit Committee with Respect to Internal Review
Regulation FD disclosure · EX-99.1 to Form 8-K
The Chemours Company Reports Fourth Quarter and Full Year 2023 Results
Results of operations · EX-99.1 to Form 8-K
Chemours Announces Dates for Fourth Quarter 2023 Earnings Release,
Regulation FD disclosure · EX-99.1 to Form 8-K
Chemours Provides update on Internal Review
Regulation FD disclosure · EX-99.1 to Form 8-K
Chemours Reschedules Earnings Release and Conference Call
Other events · EX-99.1 to Form 8-K
Chemours Announces Settlement Agreement with State of Ohio
Other events · EX-99.1 to Form 8-K